BioPharmSignal logoBioPharmSignal

Biotech News

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

SELLAS Life Sciences Group, Inc. (SLS)SELLAS Life Sciences Group, Inc.2026-06-25 13:46 ESTClinical readout

SLS (SLS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sls.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

SLSSELLAS Life Sciences Group, Inc.2026-06-25 13:46 EST

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

View all latest news

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

SLSSELLAS Life Sciences Group, Inc.2026-06-26 07:12 EST

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

SLSSELLAS Life Sciences Group, Inc.2026-06-26 07:12 EST

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

SLSSELLAS Life Sciences Group, Inc.2026-06-26 07:12 EST

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum

SLSSELLAS Life Sciences Group, Inc.2026-06-26 07:12 EST

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

SLSSELLAS Life Sciences Group, Inc.2026-06-26 07:12 EST

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States